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Abstract
The exact function of interleukin-19 (IL-19) on immune response is poorly understood. In mice, IL-19 up-regulates TNFa and
IL-6 expression and its deficiency increases susceptibility to DSS-induced colitis. In humans, IL-19 favors a Th2 response and
is elevated in several diseases. We here investigate the expression and effects of IL-19 on cells from active Crohn’s disease
(CD) patient. Twenty-three active CD patients and 20 healthy controls (HC) were included. mRNA and protein IL-19 levels
were analyzed in monocytes. IL-19 effects were determined in vitro on the T cell phenotype and in the production of
cytokines by immune cells. We observed that unstimulated and TLR-activated monocytes expressed significantly lower IL-19
mRNA in active CD patients than in HC (logFC=21.97 unstimulated; 21.88 with Pam3CSK4; and 21.91 with FSL-1; p,
0.001). These results were confirmed at protein level. Exogenous IL-19 had an anti-inflammatory effect on HC but not on CD
patients. IL-19 decreased TNFa production in PBMC (850.7675.29 pg/ml vs 2626.06350 pg/ml; p,0.01) and increased
CTLA4 expression (22.0461.55% vs 13.9862.05%; p,0.05) and IL-4 production (32.568.9 pg/ml vs 13.562.9 pg/ml; p,
0.05) in T cells from HC. IL-10 regulated IL-19 production in both active CD patients and HC. We observed that three of the
miRNAs that can modulate IL-19 mRNA expression, were up-regulated in monocytes from active CD patients. These results
suggested that IL-19 had an anti-inflammatory role in this study. Defects in IL-19 expression and the lack of response to this
cytokine could contribute to inflammatory mechanisms in active CD patients.
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Introduction
IL-19 is mainly produced by myeloid cells, B cells and epithelial
cells. It can be induced by the TLR4 ligand (LPS) and
granulocyte-macrophage colony-stimulating factor (GM-CSF).
Priming monocytes with IL-4 or IL-13 but not IFNc significantly
increases the levels of IL-19 mRNA induced by subsequent
stimulation with LPS [1]. IL-19 functions through a receptor
complex consisting of IL-20Ra and IL-20Rb that is also used by
IL-20 and IL-24 [2]. High levels of both receptor chains are
present in several tissues, including skin, lung, heart, small
intestine, salivary glands, and testes. Expression of the IL20Ra
chain has not been detected on human leukocytes to date,
suggesting that immune cells are only a minor target for the effects
of IL-19 [3]. However, these results are not conclusive because
other studies have shown that IL-19 enhances the production of
Th2 cytokines in T cells [4] and IL-10 but not TNFa in
unstimulated monocytes [5]. In addition, it has been reported the
effects of IL-19 on human and mouse immune cells differ because
it induces IL-6 and TNFa in mice but not in humans [6].
Recently, Ching-Hua Yeh et al. reported that the serum levels of
IL-19 correlate inversely with the levels of IFNc-secreted CD4+T
cells after PMA/ionomycin stimulation. These authors showed
that IL-19 up-regulates Foxp3 mRNA and induces the regulatory
function of human CD4+ T cells. Altogether these results suggest
that IL-19 plays an intriguing role during the immune response
[7].
IL-19 is elevated in asthma patients [8] and in uremic patients
[9]. It is also involved in the pathogenesis of psoriasis [10,11],
neoplastic processes [12,13], endotoxic shock [14], chronic
rhinosinusitis [15], vascular disease [16,17,18], and rheumatoid
arthritis [19,20,21]. Regarding IL-19 effects in vivo, Azuma et al.
[22] reported that IL-19-deficient mice are more susceptible to
experimental acute colitis induced by dextran sodium sulfate (DSS)
than wild type (WT) mice. Crohn’s disease (CD) is an inflamma-
tory bowel disease (IBD). Its etiopathogenesis remains poorly
understood, but it includes genetic susceptibility, enteric environ-
mental factors and immunological responses. It is characterized by
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an imbalanced activation of Th1 and Th2 dependent immune
responses. Activated cells from CD patients produce higher levels
of IFNc, IL-17 and TNFa [23,24]. Increased expression of
intracellular IL-2, IL-6, and IL-10 in active Crohn’s disease
patients has also been reported [25]. Besides, a central immuno-
logical imbalance favors the development of disease in mice [26].
Knockout mice for IL-2 [27] and IL-10 [28] spontaneously
develop colitis, and it was recently documented that IL-19-
deficient mice present increased susceptibility to acute DSS-
induced colitis. This increased susceptibility correlated with the
accumulation of macrophages and the increased expression of
many different cytokines (IFNc, IL-1b, IL-6, IL-12 and TNFa).
Bone marrow derived macrophages from IL-19-deficient mice
produced higher levels of TNFa, IL-6 and IL-12 than WT mice
after LPS stimulation, suggesting a role for IL-19 in the innate
response to microbial stimuli.
In the present study we aimed to address the expression,
regulation and effect of IL-19 in active CD patients. We
determined mRNA, protein levels of IL-19 and the effect of this
cytokine on immune cell cultures from active CD patients and
healthy controls (HC).
Materials and Methods
Peripheral Blood Samples
Peripheral blood samples were collected from healthy controls
and active CD patients.
Written informed consent was obtained from all participants
and ethical approval for the study was granted by the Hospital de
la Santa Creu i Sant Pau Institutional Ethics Committees.
Institutional Ethics Committee approved this consent procedure.
Twenty-three patients with CD attending the IBD outpatient
clinic were included in the study. Table 1 shows the demographic
and clinical relevant data of the CD enrolled patients according to
Montreal classification for age at onset; disease location and
behaviour. Twenty age- and sex-matched HC were also evaluated.
CD diagnoses were based on clinical, radiologic, endoscopic and
pathological bases. All of the patients had active disease at the time
of blood collection. To avoid the influence of treatment in our
analysis, we selected a cohort of active CD patients who were not
receiving immunomodulators in the 6 months prior to blood
collection. Peripheral blood mononuclear cells (PBMC) were
isolated by Ficoll-Hypaque (Lymphoprep, Axis-Shield PoC As,
Oslo, Norway) density gradient centrifugation. Cells were washed
twice, resuspended in FCS+10% DMSO, placed in cryogenic vials
and kept in liquid nitrogen until needed.
Purification of Monocytes
Monocytes were obtained from PBMC by negative selection
using the Human Monocyte Enrichment KIT (EasySep StemCell,
Grenoble, France). The viability of recovered non-touched
population was determined by Trypan Blue (.99%). The purity
of monocytes was evaluated by flow cytometry and was always .
95%.
Genotyping of TLR1 Variants
As TLR1 polymorphism can influence cytokine production
after Pam3CSK4 activation [29], TLR1 602 alleles (I/S, I/I, S/S)
were determined in genomic DNA extracted from blood samples
using Qiagen kit (Qiagen, Heiden, Germany). The primers used
were 59 AGGGGACAATCCATTCCAAT 39 and 59 GGGCAC-
GATTCTTTCTGGG39. Once the amplification was confirmed,
sequencing was performed by Mocrogen Inc, Korea using BigDye
(Applied Biosystems, Life Technologies, Camarillo CA, USA)
chemistry.
Cell Culture
PBMC or purified monocytes were cultured (16106 cells/ml) in
complete RPMI 1640 medium (BioWhittaker, Verviers, Belgium)
including 10% fetal calf serum, 2 mM glutamine, 100 U/ml
penicillin and 100 mg/ml streptomycin (Biowhittaker) and with
TLRs agonists: TLR2/TLR6 agonist, FSL-1 (0.01 mg/ml),
TLR2/TLR1 agonist, Pam3CSK4 (0.1 mg/ml) and TLR4 ago-
nist, LPS (0.2 mg/ml) (Invivogen, San Diego, CA). To analyze the
effect of exogenous IL-19, PBMC were treated with rhIL-19
(400 ng/ml) (ImmunoTools, Friesoythe, Germany). To study the
effect of IL-10 on IL-19 production, rhIL-10 (200 ng/ml)
(Preprotech, USA) and blocking anti-IL-10 (500 ng/ml) (BD,
Biosciences, USA) were added to PBMC cultures.
Measurement of Cytokine Concentration
IL-19 content in serum and after TLR activation was
determined using Quantikine Human IL-19 Immunoassay (R&D
systems. Minneapolis MN USA). Supernatants from cell cultures
were tested for TNFa, IL-10, IFNc (BD) and IL-4 (Immunotools)
content by specific ELISA, according to the manufacturer’s
instructions, using the quantitative colorimetric sandwich ELISA
kit.
T cell Activation and Expansion
PBMC from active CD patients and HC were activated and
expanded using T cell Activation Expansion Kit (Milteny Biotec.
Germany). Cultures were performed with or without rhIL-19
(400 ng/ml), and after 3 and 9 days of culture, cells were removed
and their phenotype was analyzed by flow cytometry.
Flow Cytometry
To analyze T cell phenotype after 3 and 9 days of activation and
expansion culture, cells were removed and labeled with anti-CD4-
PECy7 (Biolegend, San Diego, CA, USA), anti-CD25-FITC
(Immunotools), anti-CD127-Alexa647 (BD), and anti-CTLA4-PE
(BD) or anti-GITR-PE (BioLegend) or the corresponding isotype
control Igs. Stained cells were analyzed by flow cytometry with
Cytomics FC 500 (Beckman Coulter, Miami, FL).
RNA Isolation
Total RNA from purified monocytes cultured with medium or
with Pam3CSK4 and FSL-1 ligands was purified using the Mini
Qiagen Kit RNA (Hilden, Germany). RNA was resuspended in
RNase-free H2O and stored at 280uC until use. RNA concen-
tration was determined using a NanoDrop spectophotometer
(Thermo Fisher Scientific, Wilmington, DE, USA) and RNA
integrity number (RIN) was analyzed using a RNA 6000 Nano
LabChip Kit (Agilent Technologies, Boeblingen, Germany) with
an Agilent 2100 Bioanalyzer according to the manufacturer’s
instructions. All samples used in this study had a RIN.9.0.
Microarray Hybridization and Data Analysis
Microarray analysis was performed using Affymetrix GeneChip
Human Gene U133A 2.0 Array (HG-U133A) (Affymetrix, Santa
Clara, CA, USA) according to the manufacturer’s instructions.
Briefly, isolated RNA (100 ng) was reverse transcribed to double-
stranded cDNA. In vitro transcription synthesis of aRNA was
performed at 40uC during 16 h. In all cases, 12 mg of each aRNA
preparation was fragmented and hybridized onto a GeneChip
Human Gene U133A 2.0 Array for 16 hours in a Hybridization
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Oven 640 (Affymetrix). The arrays then were washed and stained
on a GeneChip Fluidics Station 450 (Affymetrix). Scanned images
were converted to CEL files by GeneChip Command Console
Software (AGCC) (Affymetrix). Raw expression values were pre-
processed using the Robust Multiarray Averaging method. These
normalized values were used for all subsequent analyses. Data
were subjected to non-specific filtering to remove low signal and
low variability genes. The selection of differentially expressed
genes was based on a linear model analysis with empirical Bayes
modification for the variance estimates. p-values were adjusted to
obtain a strong control over the false discovery rate using the
Benjamini-Hochberg method.
Quantification of miRNA Expression Level
Total RNA enriched with small RNAs was obtained from
purified monocytes from HC and active CD patients using
mirVana miRNA Isolation Kit (Ambion, Invitrogen, Life Tech-
nologies). The small RNA fractions were reverse transcribed using
Megaplex RT primers and the expression level of 384 miRNAs
was analysed using TaqMan MicroRNA Arrays (Array A)
(Applied Biosystems, Life Technologies). Experimental data were
analyzed by DataAssist Software (Life Technologies). The relative
miRNA expression values were calculated using RNU44 as
endogenous control.
Real Time RT-PCR
Using specific microRNA primers, cDNA from RNA was
synthesized with TaqMan MicroRNA Reverse Transcription Kit
(Applied Biosystems, Life Technologies). Real-Time PCR was
performed from 1.33 ml of cDNA products using TaqMan
Universal PCR Master Mix, no UNG and the TaqMan Small
RNA assays. All expression levels were normalized to an
endogenous control RNU44. Experimental data were analyzed
by DataAssist Software (Life Technologies).
Statistical Analysis
Statistical analyses were performed with GraphPad Prism 5.0
(GraphPad Software Inc. San Diego CA). Data are presented as
mean 6 SEM. Differences were determined by student’s unpaired
t-test or the Mann-Whitney U-test and paired t test or Wilcoxon
matched pairs test when samples are related, depending on
Gaussian approximation.
Results
Impaired IL-19 Gene Expression in Monocytes from
Active CD Patients
In a microarray analysis of purified monocytes heterozygous for
the TLR1 SNP I602S, we identified genes that were differentially
down-regulated in monocytes from active CD patients compared
to monocytes from HC (53 genes in monocytes cultured with
medium; 78 genes in monocytes cultured with Pam3CSK4 and 60
genes in monocytes cultured with FSL-1) (data not shown). Among
down-regulated genes in monocytes from active CD patients, we
found IL-19, a cytokine related to the IL-10 family (Fig. 1A). We
observed significant differences in the mRNA levels for IL-19
between CD patients and HC after 6 h of culture in medium and
after TLR activation. IL-19 mRNA in CD monocytes was
significantly lower than in HC monocytes in all conditions
assayed. As shown in Figure 1B, after 6 h of culture, the logFC
in IL-19 expression between monocytes isolated from active CD
patients vs HC was: 21.97 with medium (p,0.001); 21.88 with
Pam3CSK4 (p,0.001) and 21.91 with FSL-1 (p,0.001). After
TLR2 activation, monocytes from active CD patients and HC
increased IL-19 mRNA levels (logFC 1.01, p adjusted ,0.01 after
Pam3CSK4 activation, logFC 1.017 p adjusted ,0.01 after FSL-1
activation).
Table 1. Demographic and clinical characteristics of patients included in this study.
Active CD patients
Age (year): 43.59615.92
Sex: Men: 37.5%
Women: 62.5%
Age at diagnosis: A1 (below 16 years) = 0%
A2 (between 17–40 years) = 82.6%
A3 (above 40) = 17.4%
Location: L1 (ileal) = 39.2%
L2 (colonic) = 47.8%
L3 (ileocolonic) = 13.0%
Behaviour: B1 (non-stricturing) = 100%
Activity: Mild: 30%
Moderate: 52.1%
Severe: 17.3%
Perianal: Yes: 22.2%
No: 77.78%
Surgery: Yes: 24.3%
No: 75.7%
Smoke: Yes: 60%
No: 40%
doi:10.1371/journal.pone.0093910.t001
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TLR Activation Increases the Production of IL-19 in
Monocytes and PBMC
To analyze IL-19 at protein level purified monocytes and
PBMC from active CD patients and HC were cultured for 24 h
and 48 h in the presence of TLRs ligands. Purified monocytes
from active CD patients cultured with medium released lower
amounts of IL-19 than HC after 24 h of culture (3456306 pg/ml
vs 176961026 pg/ml, respectively). After TLR stimulation, both
types of cells increased the release of IL-19 (CD: LPS:
5686622 pg/ml; Pam3CSK4:7406819 pg/ml; FSL-
1:9806991 pg/ml vs HC: LPS: 24336216 pg/ml;
Pam3CSK4:25586169 pg/ml; FSL-1:2284638 pg/ml). To de-
termine whether lymphocytes alter IL-19 production by mono-
cytes, we cultured PBMC from active CD patients and HC. At
24 h of culture with medium, PBMCs from CD produced
significantly lower levels of IL-19 (CD: 2667.63 pg/ml of IL-19
vs HC: 4086143.1 pg/ml of IL-19 (p,0.05) (Fig. 2A). After TLR
activation with TLR4 and TLR2 ligands, PBMC from active CD
patients also secreted significantly lower amounts of IL-19 than
PBMC from HC (LPS: 150.3617.53 vs 606.7639.53; p,0.001;
Pam3CSK4:147.0650.82 vs 595.8681.85; p,0.01; FSL-
1:101.0619.15 vs 472.0637.83; p,0.001). Similar results were
obtained after 48 h of culture with medium and in the presence of
TLR ligands (Fig. 2B) (CD: medium: 19.563.5 pg/ml; LPS:
208.7659.38 pg/ml; Pam3CSK4:126.3628.75 pg/ml; FSL-
1:183.0679.1 pg/ml vs HC: medium: 2126145 pg/ml; LPS:
7016109.1 pg/ml; Pam3CSK4:721.06150 pg/ml; FSL-
1:660.76129.9 pg/ml). Consistent with a decreased production
of IL-19 in monocytes and PBMC from active CD patients, the
content of total circulating IL-19 showed a tendency to decrease in
serum of active CD patients (CD: 19.0368.06 pg/ml vs HC:
28.27610.27 pg/ml) (data not shown).
rhIL-19 Decreases TNFa Production
To analyze functional consequences of the decreased IL-19
production in active CD patients, we added exogenous IL-19 in
PBMC cultures. PBMC from active CD patients and HC were
activated with TLR4 and TLR2 ligands for 24 h in the presence
or absence of rhIL-19. Supernatants were collected and TNFa and
IL-10 were determined. As expected from our previous work [23]
after LPS and Pam3CSK4 activation, PBMCs from CD patients
produced higher amounts of TNFa than HC (2626.06350 pg/ml
vs 850.7675.29 pg/ml, p,0.01 and 1068.06355.6 pg/ml vs
254.0684.54 pg/ml p,0.05). In contrast, after FSL-1 activation,
Figure 1. Heat map image of IL-10 family cytokines. Monocytes mRNA was extracted from HC (n = 3) and active CD patients (n = 3) after 6 h of
culture with medium in the absence or presence of Pam3CSK4 and FSL-1. A) Green denoted down-regulated and red up-regulated genes. B) logFC of
IL-19 mRNA expression between CD and HC are shown. **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0093910.g001
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we observed a similar TNFa production in CD and HC PBMCs
(337.0659.99 pg/ml vs 485.86218.9 pg/ml). After LPS activa-
tion, PBMCs from active CD patients produced higher amounts of
IL-10 than HC (658.86112.7 pg/ml vs 341.0668.19 pg/ml p,
0.05). However, after TLR2 activation, PBMCs from active CD
patients and HC produced similar amounts of IL-10 (Fig. 3). We
could not confirm that differences in TNFa production were partly
associated with the percentage of monocytes in these samples.
However, in our previous results [23] no significant differences in
the percentage of monocytes in PBMC was observed between
active CD patients and HC.
When we added rhIL-19 to cell cultures, the pattern of cytokine
production changed. Addition of rhIL-19 significantly decreased
TNFa production in LPS cultures of PBMC from HC
(850.7675.29 pg/ml vs 610.96105.1, p,0.05), but not from
active CD patients (2626.06350 pg/m vs 2965.16588.5 pg/m)
(Fig. 3A and 3D). Addition of rhIL-19 induced no changes in
TNFa production after TLR2 activation and no changes in IL-10
after TLR2 or TLR4 activation. (Fig. 3B and 3E).
To compare the effect produced by IL-19 and IL-10 on TNFa
production, PBMC were cultured in the presence of rhIL-10.
Addition of IL-10 significantly decreased TNFa production in LPS
cultures (CD: 1255.06153.6 pg/ml vs 44.0625.4 pg/ml, p,0.01;
HC 808686.16 pg/ml vs 12.066.9 pg/ml, p,0.01) and in FSL-1
cultures (CD: 261.3656.26 pg/ml vs 53.67628.6 pg/ml, p,0.05;
HC: 485.86218.9 pg/ml vs 66.6637.0 pg/ml, p,0.05) (Fig. 3F
and 3C).
IL-19 Up-regulates IL-4 on Activated T Cells
To study the effect of rhIL-19 on T cells, long exposure cultures
to IL-19 were performed [4,8]. Similar percentage of CD4+ cells
were observed in PBMC from active CD patients and HC (% of
CD4+ cells expressed as mean 6 SD: 27.77612.21 and
22.2368.91, respectively; n = 8; p=0.3178) before culture. T cells
from active CD patients and HC were activated and expanded for
9 days. Supernatants were removed and cytokine content was
determined. As shown in Figure 4, after 9 days of culture, the
addition of rhIL-19 to HC cultures increased IL-4 production
(HC: 32.568.9 pg/ml with IL-19 vs 13.562.9 pg/ml without IL-
19, p,0.05) whereas IL-4 content remained unaffected in active
CD cultures (15.1767.0 pg/ml with IL-19 vs 19.3369.9 pg/ml
without IL-19). Normalized values of IL-4 production in relation
to the % of CD4+ cells also indicated that IL-9 was able to
increase IL-4 production in PBMC cultures from HC but not from
active CD patients (HC: 0.6960.21 with IL-2 and 1.8160.61 with
IL-19; p,0.05; active CD patients: 0.3360.85 with IL-2 and
0.5860.313 with IL-19). No changes in IFNc content were
observed when rhIL-19 was added to cultures of active CD
patients or HC.
IL-19 Up-regulates CTLA4 Expression on CD4+ T Cells
A recent report suggested that IL-19 affects the regulatory
activity of CD4+ T cells from HC [7]. To study whether long
exposure to IL-19 can modify CD4+ phenotype in active CD
patients we performed PBMC cultures with and without rhIL-19.
We analyzed the expression on CD4+CD25+CD1272 cells of
cytotoxic T-lymphocyte antigen 4 (CTLA4) and glucocorticoid-
induced TNFR-related protein (GITR) as markers to characterize
regulatory cells in CD4+CD25+CD1272 cells [30]. Before
culturing, no expression of CTLA4 or GITR was detected on
CD4+CD25+CD1272 cells. After 3 days in culture, a low
percentage of CD4+CD25+CD1272 expressed CTLA4 but no
GITR from both active CD patients and HC (data not shown).
After 9 days, rhIL-19 increased the percentage of CD4+CD25+
CD1272CTLA4+ cells from active CD patients (24.6167.38% vs
14.7065.43%; p= 0.09) and HC (22.0461.55% vs 13.9862.05%;
p,0.05) (Fig. 5A and 5C). No differences were observed on GITR
expression in cell cultures from either active CD patients or HC in
the presence or absence of rhIL-19 (67.8666.86% vs 69.7563.9%
for active CD and 63.5867.3% vs 65.0662.72% for HC) (Fig. 5D
and 5B).
IL-10 Regulates IL-19 Production
J Williams et al 2005 [5] observed that IL-10 decreased IL-19
mRNA expression in unstimulated monocytes from HC. To
analyze whether IL-10 can regulate IL-19 production in active CD
patients after TLR activation, we cultured PBMC from active CD
patients and HC with TLR ligands in the presence or absence of
Figure 2. IL-19 production after TLR activation in PBMC cultures from active CD patients (n = 3) and HC (n = 6). PBMC were cultured
24 h (A) and 48 h (B) with different TLR ligands (LPS, Pam3CSK4 or FSL-1) and IL-19 production was determined by ELISA as described in Materials and
Methods. The viability of PBMC was determined by Trypan Blue (.99%). *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0093910.g002
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Figure 3. rhIL-19 down-regulates TNFa production in cultures from HC after LPS activation. PBMC from HC and active CD patients were
cultured with LPS (HC n= 10 and CD n= 5), Pam3CSK4 (HC n=10 and CD n=5) and FSL-1 (HC n= 5 and CD n= 3) for 24 h with or without rhIL-19
(400 ng/ml). A and B) TNFa and IL-10 production in cultures from HC after TLR activation with or without rhIL-19. D and E) TNFa and IL-10 production
in cultures from active CD patients after TLR activation with or without rhIL-19. C and F) TNFa production from HC and active CD patients cultured
with rhIL-10 (200 ng/ml). *p,0.05.
doi:10.1371/journal.pone.0093910.g003
Figure 4. rhIL-19 up-regulates IL-4 production in activated T cells. PBMC from HC (n= 6) and active CD (n= 6) were activated and expanded
with anti-CD3+anti-CD2+anti-CD28 as described in Materials and Methods. Supernatants were removed and IL-4 and IFNc content were analyzed by
ELISA. A) A) Up-regulation of IL-4 by rhIL-19 in HC cultures. B) IFNc content in HC and CD patients in the presence or absence of rhIL-19.*p,0.05.
doi:10.1371/journal.pone.0093910.g004
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rhIL-10. In all assays, IL-19 production decreased when rhIL-10
was added to cultures. Furthermore, IL-19 production increased
similarly in active CD patients and HC when anti-IL-10 blocking
antibodies were added to the Pam3CSK4 and FSL-1 cultures but
not to LPS cultures (Fig. 6A and 6B). IL-19 production was
similarly regulated by IL-10 in HC and CD patients.
Three miRNAs Targeting IL-19 are Up-regulated in Active
CD Patients
We next analyzed whether the lower levels of IL-19 mRNA in
CD patients were a consequence of the up-regulation of specific
miRNAs targeting IL-19. To this end, purified monocytes were
cultured and after 3 h, RNA enriched with miRNA was extracted
and the expression of 384 miRNAs was analyzed. Computational
prediction of IL-19 mRNA targets for miRNAs was carried out
with Microcosm Targets (http://www.ebi.ac.uk/enright-srv/
microcosm/htdocs/targets/v5/) [31]. Silico analysis let us to
identify statistically significant (p,0.05) potential binding sites in
the IL-19 mRNA for three up regulated miRNAs in monocytes
from active CD patients: hsa-miRNA 101 (at position 302–322,
score 15.5693), hsa-miRNA 340 (at position 70–91, score
16.6028), and hsa-miRNA 454 (at position 298–320, score
18.1842) (Fig. 7).
Discussion
We found that active CD patients had an additional defect in
the regulation of the immune response. Monocytes from active
CD patients had lower IL-19 expression than those from HC. In
addition, PBMC from CD did not respond to IL-19. On the
contrary, cells from HC responded to IL-19, decreasing TNFa
and increasing IL-4 production and CTLA4 expression. This
response in HC confirms the anti-inflammatory role of IL-19.
Low IL-19 expression and production may contribute to CD
etiopathology. This possibility is supported by the experiments of
Azuma et al who showed that IL-192/2 mice have higher
susceptibility to acute DSS-induced colitis than wild-type mice.
Their deficient mice expressed higher amounts of IL-6, TNFa and
IL12 but no change in IL-10 after TLR4 activation [22].
Similarly, we showed that monocytes from active CD patients
produced more TNFa than healthy donors in response to TLRs.
Figure 5. rhIL-19 up-regulates CTLA4 expression on CD4+CD25+CD1272 cells. PBMC from HC (n= 4) and active CD (n = 3) were activated
with anti-CD3+anti-CD2+anti-CD28 as described in Materials and Methods. The expression of CTLA4 (A) and GITR (B) was determined on CD4+CD25+
CD1272 cells by flow cytometry. *p,0.05.
doi:10.1371/journal.pone.0093910.g005
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Our findings suggest two regulatory mechanisms to explain the
low IL-19 expression in active CD patients. One mechanism could
be the regulation at gene transcription. IL-19 lies in a cluster of
four IL-10 family member genes. The IL-19 promoter contains
binding motifs for keratinocyte growth factor (FGF7), two NF-kB
sites and two CAAT enhancer binding protein sites. Key elements
of control over the IL-19 promoter are an AML1 site (RUNX1)
and the STAT6 sites [32]. Interestingly, unpublished data from
our microarray analysis showed that monocytes from active CD
patients express lower levels of STAT6 and FGF7 than monocytes
from HC. Another mechanism could be the epigenetic regulation
by miRNAs. miRNAs are described as small noncoding RNAs
that regulate gene expression by binding to complementary target
mRNAs, promoting mRNA decay or inhibiting mRNA translation
[33]. Based on computational prediction we observed that three
miRNAs that can modulate IL-19 mRNA expression (hsa-miRNA
101, hsa-miRNA 340 and hsa-miRNA 454) were up-regulated in
monocytes from active CD patients (Fig. 7). Consistent with our
observation, mirRNA-101 was up-regulated in the peripheral
blood lymphocytes of an experimental model of TH1-mediated
inflammatory bowel disease [34]. We cannot rule out other
regulatory mechanisms such as the methylation status of IL-19
gene. However, this is a controversial issue. One study reported
that the IL-19 gene was hypomethylated in whole blood from ileal
inactive CD female patients when compared to HC [35].
However, another study found that the murine IL-19 gene was
Figure 6. IL-10 regulates IL-19 expression. PBMC from A) HC (n = 3) and B) active CD patients (n = 3) were activated 24 h with TLR ligands (LPS,
Pam3CSK4 and FSL-1) in the presence of rhIL-10 (200 ng/ml) and blocking anti-IL10 (500 ng/ml). Results are expressed as: (IL19 production with TLR+
rhIL-10 or anti-IL10-IL-19 production with TLR)/IL-19 production with TLR.
doi:10.1371/journal.pone.0093910.g006
Figure 7. Three miRNAs targeting IL-19 are up-regulated in active CD patients. miRNA expression in purified monocytes from HC (n= 3)
and active CD patients (n = 5) were determined by RT-PCR as described in Materials and Methods. Different expression is shown as Delta Ct values.
**p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0093910.g007
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methylated in CD4+T lymphocytes, and as a result, IL-19 was not
transcribed in T cells from these mice [36]. Taken together, these
data suggest that IL-19 expression is tightly regulated. Further
studies are needed to clarify the mechanism that restrains IL-19
mRNA expression in monocytes from active CD patients.
The exact role of IL-19 in the immune response is not well
understood. IL-19 is recognized and signals through IL-20Ra and
IL-20Rb [37]. Some authors have questioned the IL-19 role in
regulating immune cells due to undetectable IL-20Ra chain
expression on freshly isolated leukocytes and differentiated
macrophages or dendritic cells [37,38]. Other authors have shown
that Th2 cell lines, but not Th1 cell lines, had detectable mRNA
levels of IL-20Ra [39]. In addition, several studies have described
IL-19 effects on T cells and monocytes [5,7,8,9,40]. Our findings
support these latter observations and suggest that exogenous IL-19
has an anti-inflammatory effect on immune cells from HC. We
showed that IL-19 decreased TLR4-induced TNFa production in
PBMC cultures from HC but not from active CD patients. Like
other authors, we also found that long exposure to IL-19 has two
kinds of effects on HC T cells [4,8]. First, it increased expression of
IL-4 but not IFNc, suggesting that IL-19 is capable of inducing
Th2 response in T cells. This possibility is supported by the
increased levels to IL-19 levels found in asthma and uremia, two
Th2 behavior diseases [8,9]. Second, long exposure of IL-19
significantly increases CTLA4 but not GITR expression on Treg
cells (CD4+CD25+CD1272) from HC but not from active CD
patients, suggesting that IL-19 influences the Treg phenotype. Yeh
Ching-Hua similarly found that rhIL-19 induced a regulatory
phenotype (FOXP3) and regulatory function on CD4 T cells from
HC [7]. Taken together, these results show that IL-19 acts
differently on PBMC from HC and active CD patients.
Several hypotheses could explain the different response of cells
from active CD patients and HC to IL-19. One explanation is that
monocytes from active CD patients and HC might express distinct
protein levels of IL-20Ra and/or IL20Rb. However, at the
mRNA level, we observed that monocytes from active CD patients
and HC expressed similar but low levels of IL-20Ra controls
(expression level as mean 6 SD: 3.0760.11 and 3.1060.03,
respectively). Furthermore, published results showed undetectable
levels of IL-20Ra by PCR [37,38,41]. No results have been
published about expression of IL-20Rb on the cell surface of
mononuclear cells from peripheral blood. In view of its sensitivity
and unicellular analysis, flow cytometry will likely be the final
demonstration of IL-20R protein expression on the surface of
monocytes and T cells. Unfortunately, monoclonal IL-20R
antibodies for cytometry are not currently available.
Another explanation for the different IL-19 response in active
CD patients may be altered protein expression or activity for
downstream IL-20R molecules (STAT3, STAT1, TyK and JAK1,
etc) or different affinity for exogenous IL-19 by IL-20R. However,
other groups showed that a short exposure to IL-19 failed to
phosphorylate STAT3 in mononuclear cels from peripheral blood
[40]. In view of these results, we cannot rule out that IL-19 could
signal through another pathway in immune cells.
Our findings showed that IL-19 was regulated not only by IL-10
but also by other TLR4 induced factors. In this regard, addition of
rhIL-10 to cell cultures inhibited IL-19 protein production by
monocytes from active CD patients and HC during TLR4 and
TLR2 activation. Previous reports have shown that IL-10
decreased IL-19 expression in unstimulated cultures at mRNA
level [5]. Inversely, blocking IL-10 induced the expression of IL-19
by monocytes activated by TLR2 but not by TLR4 ligands. This
observation suggests that activation of TLR4 leads to the
expression of other unknown factors controlling IL-19 production
by monocytes from active CD patients and HC.
Although IL-19 and IL-10 are both members of the IL-10
family, we found that the two cytokines had different effects on
monocytes. IL-19 only decreased TNFa production via TLR4 in
HC. However, IL-10 diminished the production of TNFa via
TLR4 and via TLR2 in HC and active CD patients. PBMC from
active CD patients were then able to respond to IL-10 but not to
IL-19.
In conclusion, we have shown that IL-19 can work as a
regulatory cytokine in the inflammatory response of immune cells.
Our findings suggest that defects in IL-19 expression and the lack
of response to this cytokine may contribute to the inflammatory
mechanisms described for active CD patients.
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